Skip to content
    Font Size

    Metformin May Lower Risk of Prostate Cancer Death

    Diabetic men using the drug had higher survival rates in cancer study

    WebMD News from HealthDay

    By Kathleen Doheny

    HealthDay Reporter

    MONDAY, Aug. 5 (HealthDay News) -- Metformin, a widely used diabetes drug, may reduce the risk of dying from prostate cancer, according to new research.

    A study of nearly 4,000 diabetic men found that those taking metformin when diagnosed with prostate cancer were less likely to die of the cancer or other causes compared to men using other diabetes drugs.

    "We demonstrated that metformin is associated with improved survival among diabetic patients with prostate cancer," said Dr. David Margel, a uro-oncologist at Rabin Medical Center in Petah Tikva, Israel, who conducted the research while at the University of Toronto.

    "It's associated in a dose-response manner," he said. "The longer you were on metformin, the less likely you were to die of prostate cancer and of all causes."

    But whether metformin can prevent prostate cancer progression in people without diabetes remains to be seen, experts say.

    Diabetes and prostate cancer are common in the United States. This year, about 239,000 new cases of prostate cancer will be diagnosed, and more than 29,000 men will die from it, according to the American Cancer Society.

    Type 2 diabetes is rampant, and metformin is the drug most commonly prescribed to treat it. More than 61 million metformin prescriptions were filled in the United States last year. Brand names include Glucophage and Glumetza. The drug, in its generic forms and certain brand names, is relatively inexpensive.

    Previous research has focused on whether metformin might reduce the risk of getting prostate cancer, but most studies were negative. Some experts believe the drug instead works to improve survival once the cancer occurs.

    In the new study, published online Aug. 5 in the Journal of Clinical Oncology, Margel looked at more than 3,800 diabetic men aged 67 or older who lived in Ontario. About one-third were taking metformin at the study's start. Others were using different diabetes drugs.

    The men took the metformin for a median of 19 months (half longer than that, half shorter) before the cancer was diagnosed and nearly nine months after.

    Today on WebMD

    man with doctor
    Symptoms, risks, treatments
    man coughing
    Men shouldn’t ignore
    prostate cancer cells
    What does this diagnosis mean?
    doctor and male patient
    Is it worth it?
    cancer fighting foods
    15 Cancer Symptoms Men Ignore
    Prostate Enlarged
    Picture Of The Prostate
    Prostate Cancer Quiz
    screening tests for men
    Prostate Cancer Symptoms
    Vitamin D